Skip to main content

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

The phase 2 trial (NCT03881059) was previously published in 2022 and included 203 PsA patients randomized to to placebo, deucravacitinib 6 mg once daily (QD), or deucravacitinib 12 mg QD.  At week 16, ACR-20 responses were significantly higher with deucravacitinib 6 mg (52.9%) and 12 mg once a day (62.7%) compared to placebo (31.8%). Both deucravacitinib doses were significant superior to placebo (p≤0.05). 

Serum biomarkers were assess at several time points and included those of IL-23 pathway (IL-17A, BD-2, and IL-19), Type I interferon pathway, inflammation, and collagen matrix turnover. 

At baseline IL-17A, BD-2, and IL-19 had a modest association with PASI scores (r=0.4, r=0.56, and r=0.5, respectively). 

At week 16 (primary endpoint) IL-17A, BD-2, IL-19, CXCL-9, CXCL-10, CRP, MMP3, and C4M levels were significantly reduced in patients on In deucravacitinib (P<0.01). 

Higher levels of IL-23 associated biomarkers predicted higher PASI 75 and ACR 20 response rates in deucravacitinib-treated patients. Better PASI 75 response rates were seen in deucravicitinib treated PsA patients with high baseline IL-17A (OR: 15.76) and BD-2 (OR: 15.41).

Deucravacitinib inhibition of TYK2 signaling affects IL-23 and Type I IFN pathway, as well as collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject